Social anxiety disorder (SAD) is among the most ubiquitous emotional disorders with a lifetime prevalence of 12.1% [1] . Individuals with SAD often experience an unremitting course associated with numerous functional impairments and diminished quality of life [1] [2] [3] [4] . Although cognitive behavior therapy (CBT) is regarded as one of the most efficacious treatments for SAD [5] [6] , pharmacological interventions are more prevalent and widely utilized. Of the various pharmacological interventions that have been applied to SAD, most published randomized controlled trials have examined the efficacy of antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs)), monoamine oxidase inhibitors (MAOIs), and benzodiazepines. Despite the fact that prior research has substantiated the efficacy of these pharmacological treatments, relatively little is known about the potential mechanisms underlying pharmacotherapy [7] .
Indeed, a number of individual treatment mechanisms have been investigated in CBT, such as changes in estimated social cost and extinction learning [8] [9] . Extant literature suggests that antidepressants and MAOIs are associated with improvement in more general mental health domains such as quality of life (QOL) [10] [11] . As regards pharmacotherapy, it may be the case that it exerts its therapeutic effect on QOL by way of reducing symptoms of social anxiety.
We collected data on pharmacotherapy class, number of participants, length of pharmacotherapy (in weeks), mean age, percentage of male/female participants, and initial severity. Study bias was assessed with the Cochrane risk of bias instrument. This tool involves assessing each study as containing a high, low or unclear level of bias risk in a number of domains using pre-specified criteria. The domains used in our assessment were: 1) Sequence Generation, which assesses whether allocation of participants to treatment condition are adequately generated in a random manner; 2) Allocation Concealment, which assesses whether treatment assignment was adequately concealed from investigators and participants prior to randomization; 3) Incomplete Outcome Data, which assesses whether outcome data are missing at random and imputed using appropriate methods; and 4) Selective Outcome Reporting, which determines whether pre-specified outcome variables of interest are adequately and completely reported. Following recommendations from the Cochrane guidelines, a total bias assessment was created for each study such that an 'unclear' rating in any category meant an 'unclear risk' overall rating unless there was a 'high' rating in any category, which lead to a 'high risk' overall rating. 'Low risk' studies had to be rated as 'low' in all four categories.
We estimated controlled effect sizes using Hedges' g, which corrects for parameter bias due to small sample size [13] . To compute Hedges' g, we extracted means and standard deviations, as well as information from significance tests (e.g., t, F) [13] . The pooled effect sizes were estimated using random effects models, which assume significant heterogeneity of the included studies. All standard analyses were completed with Comprehensive Meta-Analysis [14] .
To ascertain whether symptom remission mediated improvement in QOL, meta-analytic structural equation modelling was employed to estimate the indirect effect. In this model, we determined whether the effect of treatment condition (i.e., a dummy-coded variable denoting treatment versus pill placebo) on QOL was mediated by symptom reduction. In accordance with established precedent, a two-stage structural equation modelling (TS-SEM) analysis was conducted by: (i) synthesizing correlation matrices between the X, M, and Y variables; and (ii) specifying a structural model on the pooled correlation matrix [14] . If a study did not explicitly report correlation matrices, then means, standard deviations, t-statistics, F-statistics, and effect sizes were extracted to compute correlation coefficients [16] [17] . We also pursued a reverse mediation model in which QOL mediates the relationship between treatment condition and symptom reduction. The TS-SEM model was estimated in R with the metaSEM package.
Results

Study Characteristics
Our initial search yielded 2,202 abstracts (see Figure 1) , of which 113 were deemed relevant to the current study after review and evaluated for inclusion and exclusion criteria. Of these, 67 did not meet inclusion criteria. Six studies were also identified from recently published meta-analyses [6] . The remaining 52 studies included pill placebo controlled comparisons to selective serotonin reuptake inhibitors (SSRIs; 22 studies), monoamine oxidase inhibitors (MAOIs; 7 studies), monoamine oxidase A inhibitors (MAO-As; 6 studies), serotoninnorepinephrine reuptake inhibitors (SNRIs; 3 studies), anticonvulsants (4 studies), antipsychotics (1 study), benzodiazepines (2 studies), herbal supplements (1 study), and noradrenergic and specific serotonin antidepressants (NaSSAs; 1 study). Additionally, seven studies included multiple pill placebo controlled medication comparisons, including two studies comparing an SNRI and an SSRI, one study comparing two types of SSRIs, one study comparing two types of MAOIs, one study comparing an SSRI and an NK1 receptor agonist, one study comparing an SSRI and an anticonvulsant, and one study comparing an MAOI and a beta blocker. These 52 studies with a total sample size of 12,153 individuals are depicted in Table 1 .
Overall Efficacy of Pharmacotherapy
Controlled effect sizes, confidence intervals, and significance values for each study are presented in Table 2 . The random effects meta-analysis yielded an overall, controlled effect size of Hedges' g = 0.41 (95% CI: 0.36-0.46, z = 16.34, p < .001), which suggests that pharmacotherapy contributed to greater symptom remission than pill placebo. The fail-safe N analysis was conducted to address the file drawer problem [18, 19] . If the number of studies needed to reduce the effect size to a non-significant level (i.e., the fail-safe N) exceeds 5K+10, the effect is considered robust [13] . Results of the fail-safe N analysis were robust, suggesting that it would require 7,761 future or unpublished studies with an effect size of zero to attenuate the overall effect size to non-significance. Inspection of the funnel plot reveals effect sizes distributed roughly symmetrically around the mean effect size (see Figure 2 ). Using the Trim and Fill method [20], we determined that 9 studies would need to fall to the left of the mean (i.e., have an effect size smaller than the mean) and 0 studies would need to fall to the right of the mean (i.e., have an effect size larger than the mean) to make the plot symmetrical. The randomeffects model for the new imputed mean effect size revealed a Hedges' g = 0.35 (95% CI: 0.28-0.42).
Moderator Analyses
A number of moderator analyses were conducted to determine whether treatment efficacy varies as a consequence of patient and study characteristics. A multiple meta-regression was computed with mean age, overall percentage of female participants, treatment duration, publication date, and initial severity as predictors. There was no significant relation between 
Mediator Analyses
Of all the studies included in the current meta-analysis, three studies included a 
Discussion
The current meta-analysis of 52 randomized, pill placebo controlled trials of pharmacotherapy for individuals diagnosed with SAD yielded an overall controlled effect size of Hedges's g = 0.41, which reflects a small to medium effect of pharmacotherapy for SAD. The
Fail-Safe N suggested that this effect size is robust, as 7,761 studies demonstrating null-effects would be required to attenuate the overall effect size to non-significance. Indeed, inspection of the funnel plot does not reveal substantial publication bias. Thus, the results of the current metaanalysis substantiate pharmacotherapy as an efficacious intervention for SAD.
To further understand the conditions under which pharmacotherapy is maximally efficacious, a number of treatment moderators were investigated. Consistent with a prior metaanalysis [7] , the moderator analyses provided no evidence that the efficacy of pharmacotherapy varies as a function of treatment duration, initial symptom severity, age, sex, and year of study publication. No differences in effect sizes were observed between different classes of study bias (i.e., low, high, and uncertain). Furthermore, it was also revealed that there were no significant differences between acute and long-term effects of pharmacotherapy.
In an effort to elucidate potential treatment mechanisms underlying pharmacotherapy, meta-analytic structural equation modelling was employed to assess our mediation hypothesis. Consistent with our prediction, reductions in anxiety mediated pharmacotherapy's effect on improvement in QOL. However, results of the reverse mediation were also significant, which prohibits definitive conclusions regarding temporal precedence of the mediator. Although prior research has examined neurobiological mechanisms targeted by pharmacotherapy (e.g., serotonin receptors in the case of SSRIs) [24] , there has been a relative dearth of research investigating psychological mechanisms underlying pharmacological interventions. A large literature on CBT suggests that this intervention ameliorates symptoms through a variety of treatment mechanisms (e.g., extinction learning, changes in cognitions, etc.) [8] . Despite the limited research on psychological mechanisms underlying pharmacotherapy, results of the current study indicate that it might confer its benefit on QOL by way of reductions in anxiety symptoms.
Certain limitations warrant mention. Relatively few studies examined head-to-head comparisons between different classes of active pharmacological interventions, precluding conclusions about whether a particular class of pharmacotherapy substantially outperforms another one. Because only three studies examined the effect of pharmacotherapy on QOL in SAD, it remains uncertain as to whether pharmacotherapy leads to substantial improvement in QOL. Furthermore, the results of the mediation analysis were derived from pre-to post-treatment changes in anxiety symptoms and in QOL, which do not yield the most robust test of mediation.
Future studies should better establish temporal precedence of the mediator by including more frequent assessment points to ascertain whether decreases in symptoms actually precede increases in QOL. That notwithstanding, the current meta-analysis represents a crucial first effort in determining whether changes in social anxiety mediates the efficacy of pharmacotherapy on QOL. Another important limitation concerns the significant indirect effect of the reverse mediation analysis, which prohibits firm conclusions about the directionality of mediation. Thus, it may be the case that reductions in anxiety symptoms account for improvements in QOL and vice versa. To further enhance our understanding of pharmacotherapy for SAD, future research should employ more rigorous experimental designs to better delineate the psychological mechanisms underlying pharmacological interventions. For instance, a randomized controlled trial in which both the outcome and mediator measures are assessed frequently (e.g., weekly) could enable richer conclusions as to whether changes in the mediator temporally precede changes in the outcome variable.
Conclusion
In summary, results of this meta-analysis indicate that pharmacotherapy produces greater reduction in social anxiety symptoms relative to pill placebo. Evidence of efficacy was revealed for several classes of pharmacotherapy (e.g., SSRIs, SNRIs, MAOIs, etc.). Results also suggested that pharmacotherapy may also enhance QOL. Although the mediation analyses provided evidence that pharmacotherapy produces better QOL through symptom reduction, results of the reverse mediation analysis preclude definitive interpretations regarding directionality.
Expert Opinion
Although pharmacotherapy was associated with small to medium controlled effect sizes relative to pill placebo, this suggests that there is still considerable room for improvement above and beyond potential placebo effects. Results of the current meta-analysis are in accord with prior meta-analytic research that examined the efficacy of pharmacotherapy for SAD [6] . The largest number of studies supporting the efficacy of any given class of pharmacotherapy was found for SSRIs (Hedge's g = 0.44) and MAOIs (Hedge's g = 0.36). Consistent with prior research [6] , available evidence indicates that SSRIs and MAOIs are the most reliably efficacious forms of pharmacotherapy for SAD. The current meta-analysis, however, enables us to better appreciate the underlying mechanisms that may be responsible for the efficacy of pharmacotherapy. Even though symptom reduction and improvement in QOL were corroborated as possible treatment mechanisms in the current meta-analysis, it is still possible that pharmacotherapy exerts its effect through other mechanisms. Because the studies included in the meta-analysis reported relatively few outcome variables, as almost none of them tested mediation hypotheses, it was only possible to examine a limited subset of mediators. Better understanding of the psychological mechanisms underlying pharmacotherapy is of great importance.
That notwithstanding, results of the current meta-analysis accord well with prior literature suggesting that this treatment enhances QOL in individuals diagnosed with a variety of emotional disorders [25] [26] , which tend to be very comorbid [27] [28] . This might suggest that pharmacological interventions such as SSRIs have broad spectrum effects that contribute to symptom remission across several conditions. Indeed, research attests to a strong inverse relationship between quality of life and anxiety symptoms [26] , as the presence of a disease symptom (e.g., fear about speaking up at a meeting) can be often associated with the absence of some aspect of quality of life (e.g., employment satisfaction). Therefore, it would make conceptual sense that treatment response to pharmacotherapy results from mutually reinforcing improvements in both anxiety symptoms and quality of life. He also receives royalties and payments for his editorial work from various publishers. 
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